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Aims: Reperfusion of ischaemic myocardium after acute myocardial infarction (AMI) can induce
ischaemia/reperfusion (I/R) injury, as a result of local activation of the complement system. C reactive
protein (CRP) is involved in this activation. This study analysed the potential role of IgM in complement
activation in the infarcted human myocardium.
Methods: Immunochemical analysis was carried out on heart specimens from 59 patients who died from
AMI. Serial slides of frozen tissue from the infarction site were stained for IgM, complement factors C3d
and C5b–9 (membrane attack complex), and CRP.
Results: IgM deposits were found on the plasma membrane, cross striations, and in the cytoplasm of
jeopardised cardiomyocytes in infarcts of one to five days duration. IgM depositions were remarkably
similar to those of CRP and both complement factors. The relative staining intensities of IgM and CRP
varied greatly among patients.
Conclusions: Similar to CRP, IgM targets complement locally to jeopardised cardiomyocytes in the human
heart after AMI. Localisation patterns and relative staining intensities suggest that IgM and CRP recognise
similar epitopes in the ischaemic heart, but that the relative contribution of each protein to complement
activation in the ischaemic myocardium differs among patients.
R
eperfusion of the impaired myocardium after acute
myocardial infarction (AMI) results in a local inflam-
matory response.1 This inflammatory response damages
the ischaemic tissue, a phenomenon also designated ischae-
mia/reperfusion (I/R) injury. Prevention of this I/R induced
inflammation has been shown to reduce the infarct size by as
much as 50% in animal models,1 and may offer new
therapeutic opportunities for patients with AMI. Hence,
knowledge of the mechanisms of I/R injury in humans is
warranted.
The complement system is an important mediator involved
in experimental I/R injury in animals. In a rat model of
reperfusion injury of ischaemic myocardium, prevention of
complement activation resulted in a pronounced reduction of
I/R related injury.2 In addition, there is preliminary evidence
that the inhibition of complement by C1 inhibitor reduces
infarction size by up to 57% in humans.3 These results point
to complement as an attractive target for limiting I/R injury.
However, the molecular basis of I/R induced complement
activation is not completely understood.
‘‘Prevention of ischaemia/reperfusion induced inflamma-
tion has been shown to reduce the infarct size by as much
as 50% in animal models, and may offer new therapeutic
opportunities for patients with acute myocardial infarc-
tion’’
Various molecules have been claimed to target activated
complement to the ischaemic myocardium during I/R injury.
One of these molecules is C reactive protein (CRP), which
activates complement via the classical pathway.4–6 In rabbits,
CRP was localised to the inflamed myocardium after AMI.7 8
Administration of human CRP in rats challenged with
coronary artery occlusion enhances infarction size in a
complement dependent manner.9 In myocardial tissue
specimens from patients that died from AMI, CRP colocalises
with complement,10 suggesting that in humans this acute
phase protein contributes to complement activation in the
ischaemic myocardium. This notion is supported by observa-
tions that during AMI the human heart contains increased
amounts of activation products that specifically reflect
complement activation induced by CRP.11
In mice, IgM was also shown to be involved in complement
activation induced during I/R injury.12 13 In I/R models of the
intestine and skeletal muscle, IgM deficient mice developed
substantially less I/R injury than their wild-type littermates,
and this injury was restored in the deficient mice by
supplementation with normal murine IgM. The specificity
of the IgM mediating I/R injury in mice is not known. It is
also not known whether a similar IgM dependent mechanism
occurs in humans during I/R. We hypothesised that in
humans IgM might also contribute to ischaemic injury in the
heart after AMI. Therefore, in our study we analysed tissue
specimens from the hearts of patients who had died from
AMI. These specimens were analysed for the presence of IgM,
CRP, complement factor C3d, and complement factor C5b–9
of the membrane attack complex.
METHODS
Patients
Patients referred to the department of pathology, VU Medical
Centre, Amsterdam, the Netherlands for necropsy were
included in our study if this was performed within 24 hours
of death, and when at necropsy they showed signs of a
recently developed AMI—that is, on histochemical examina-
tion they had decreased lactate dehydrogenase staining
(decoloration) of the affected myocardium. Our study was
approved by the ethics committee of the VU Medical Centre,
Amsterdam, and complied with the principles of the
Declaration of Helsinki. Use of leftover material after
Abbreviations: AMI, acute myocardial infarction; BSA, bovine serum
albumin; CRP, C reactive protein; I/R, ischaemia/reperfusion; mAb,
monoclonal antibody; PBS, phosphate buffered saline; PLA2,
phospholipase A2; PMN, polymorphonuclear leucocyte
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pathological examination is part of the standard patient
contract in our hospital.
Processing of tissue specimens
Myocardial tissue specimens were obtained from the
infarcted zone and from remote sites of the healthy part of
the heart. These remote sites showed normal lactate
dehydrogenase staining patterns and were studied as internal
non-infarcted controls. A control heart tissue sample from
the left ventricle was obtained from a patient who died from
a cause not related to heart disease. Before being prepared as
cryosections, tissue specimens were stored at 2196 C˚ (liquid
N2). Frozen sections were mounted on to SuperFrostHPlus
glass slides (Menzel-Gla¨ser, Braunschweig, Germany).
Assessment of infarct phase
Microscopic criteria14 15 were used to estimate infarct duration
and viability of cardiomyocytes in all myocardial tissue
specimens. Because morphological judgment is more reliable
with paraffin wax embedded slides, corresponding paraffin
wax slides were also made. Jeopardised myocardium was
characterised by the intensity of eosinophilic staining of
involved myofibres, condensation, loss of nuclei, and cross
striation. We characterised jeopardised myocardium without
microscopic changes but with macroscopic lactate dehydro-
genase decolorisation as an early phase infarct (phase 1),
infiltration of polymorphonuclear leucocytes (PMNs) as a
PMN phase infarct (phase 2), and infiltration of lymphocytes
and macrophages and fibrosis as a chronic phase infarct
(phase 3). Furthermore, patients showing typical changes of
phase 3 morphology together with those of phase 1
morphology were classified as reinfarct early phase (phase
4). Patients with phase 3 morphology and phase 2
morphology were classified as reinfarct PMN phase (phase
5). Two investigators (PAJK and HWMN) judged and scored
independently all slides for the infarct phase. Table 1 shows
the distribution of the various infarct phases among the
patients. In all cases, infarct age as assessed by histology
corresponded with the clinical course.
Antibodies
Horseradish peroxidase conjugated rabbit polyclonal antihu-
man IgM antibody (American Qualex, San Clemente,
California, USA) was used for immunohistochemical detec-
tion of IgM. Monoclonal antibodies (mAbs) against the
complement factor C3d (mAb C3-15; subtype, IgG1) and
against CRP (mAb 5G4; subtype, IgG2a) have been used
previously for immunohistochemical studies.10 mAb aE11
(subtype, IgG2a; Dako, Carpinteria, California, USA) was
used for the detection of complement factor C5b–9. The mAbs
were stored at 1 mg/ml in phosphate buffered saline (PBS),
pH 7.4. Irrelevant mAbs (two IgG1, one IgG2a, and one IgM)
were used as negative controls, and tested at concentrations
similar to those used for the anti-complement and anti-CRP
mAbs. These controls yielded negative results.
Immunohistochemistry
Frozen sections (5 mm thick) were mounted on to glass
slides, dried for one hour by exposure to air, and fixed in
acetone (‘‘Baker analysed reagent’’; Mallinckrodt Baker,
Deventer, the Netherlands). After rinsing in PBS, the slides
were incubated at room temperature for 10 minutes with
normal swine serum (for IgM), normal rabbit serum (for
complement and CRP) (both Dakopatts, Glostrup, Denmark),
or 5% (wt/vol) bovine serum albumin (BSA; Boehringer,
Mannheim, Germany) in PBS (for C5b–9), diluted 1/10
(normal swine serum) or 1/50 (normal rabbit serum) in 1%
(wt/vol) BSA in PBS (PBS-BSA). Incubation of the slides
with specific antibody solutions (diluted in PBS-BSA) was
performed for 60 minutes except for mAb aE11, which was
incubated overnight at 4 C˚ (the polyclonal antibody against
IgM was diluted 1/400; mAb C3-15 was diluted 1/1500; mAb
5G4 was diluted 1/300; mAb aE11 was diluted 1/50). The
slides were washed for 30 minutes with PBS and slides
stained with mAbs were incubated with horseradish perox-
idase conjugated rabbit antimouse immunoglobulins
(Dakopatts), diluted 1/25 in PBS-BSA except for mAb aE11,
which was detected using EnVision (Dako). Thereafter, the
slides were washed again in PBS and incubated for three
minutes in 0.5 mg/ml 3,39-diaminobenzidine tetrahy-
drochloride (Sigma, St Louis, Missouri, USA) in PBS,
pH 7.4, containing 0.01% (vol/vol) H2O2, washed again,
counterstained with haematoxylin for one minute, dehy-
drated, cleared, and finally mounted.
Colocalisation of IgM, C3d, C5b–9, and CRP, in addition to
the relative staining intensities of IgM and CRP were
evaluated in each patient. Furthermore, the percentage of
positive surface area was determined, by subdividing the total
area of the slide into four equal parts and then estimating the
percentage of positive area in each visual field. Finally, an
average percentage of positive surface area was calculated
from these subdivisions. The slides stained with the
polyclonal antibody against IgM, or with mAbs C3-15, 5G4,
or aE11 were serial slides.
Two investigators (PAJK and HWMN) assessed the
anatomical localisation of the specific antibodies, as visua-
lised by immunohistochemical staining. For the final scoring
results, consensus was achieved by the two investigators.
Statistics
Statistical analysis was performed with the SPSS statistical
program (Windows version 9.0). To evaluate whether
observed differences were significant, paired or non-paired
t tests were used when appropriate. A p value (two sided) of
less than 0.05 was considered to represent a significant
difference.
RESULTS
IgM deposits in the human heart
Immunohistochemical deposits of IgM were found on
cardiomyocytes that were morphologically characterised as
jeopardised (fig 1). IgM deposits were found on the plasma
membrane and were strikingly intense in different areas of
Table 1 Distribution of various phases of AMI in the patients
AMI phase Infarct age Number of patients Male/female Age range
Early phase 0–12 hours 27 17/10 23–98
PMN phase 12 hours to 5 days 11 6/5 42–85
Chronic phase 5–14 days 5 3/2 58–83
Reinfarction Chronic phase +
Early phase 0–12 hours 5 3/2 63–85
PMN phase 12 hours to 5 days 7 3/4 30–89
AMI, acute myocardial infarction; PMN, polymorphonuclear leucocyte.
IgM localises in the infarcted human heart 383
www.jclinpath.com
the macroscopic infarction zone (fig 1A–C), on cross
striations (fig 1A), and in the cytoplasm (fig 1A) of
cardiomyocytes. We used an IgM subtype antibody against
Leu7 (which is not present in cardiomyocytes of the left
ventricle of the adult heart) as a negative control, and the
results were negative (fig 1G).
Focal IgM deposits were found inconsistently on the
endothelium of blood vessels in the heart of patients who
died of AMI (not shown). This endothelial IgM staining was
independent of the phase of infarction, because within each
phase a subgroup of patients had no IgM staining of the
endothelium, whereas others had varying amounts of IgM
positive vessels. Moreover, endothelial staining for IgM was
not limited to the infarction area, but also occurred at
adjacent sites and remote areas of the healthy part of the
heart.
Figure 1 Localisation of IgM on cardiomyocytes in myocardial infarct and colocalisation of IgM, C3d, C5b–9, and C reactive protein (CRP) in the
human heart. Localisation of IgM on cardiomyocytes in the heart of a patient who had died from acute myocardial infarction (AMI): (A) IgM deposited
on the plasma membrane (arrow I), on cross striations (arrow II), and in the cytoplasm (arrow III) of jeopardised cardiomyocytes (original
magnification,6630); (B, C) high power view of IgM staining of the plasma membrane of jeopardised cardiomyocytes (arrows IV, V, and VI) (original
magnification,61000). (D, H) Localisation of IgM; (E) localisation of complement factor C3d; (F) localisation of CRP; (I) localisation of complement
factor C5b–9 in the heart of a patient who died after AMI (original magnification,6100). (G) Negative staining using an IgM subtype monoclonal
antibody against Leu7 (negative control).
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IgM deposits on cardiomyocytes were found in the
infarcted myocardium of patients with PMN phase infarcts
and PMN phase reinfarcts. No depositions of IgM were found
in the infarcted myocardium of patients with early or chronic
phase infarcts or early reinfarcts. IgM deposits were never
found in the healthy, remote myocardium. In addition, no
IgM was found on the cardiomyocytes of a heart from a
patient who died of non-heart disease related causes. As
discussed earlier, no staining with IgG1 or IgG2a was found
on cardiomyocytes. The replacement of specific antibody with
IgG1 or IgG2a isotype controls yielded negative results in the
cardiomyocytes.
Colocalisation of IgM, complement, and CRP
To test for the putative colocalisation of IgM, complement,
and CRP in the infarcted myocardium, we stained serial
slides of the tissue specimens. IgM (fig 1D, H) colocalised
with complement factor C3d (fig 1E), complement factor
C5b–9 (fig 1I), and CRP (fig 1F)—the staining patterns of
IgM, CRP, and complement were strikingly similar. As was
found for IgM, no complement or CRP deposits occurred at
sites remote from the infarction area.
We also determined the extent of the deposits by
estimating the mean surface area occupied by cardiomyocytes
that were positive for IgM, complement, or CRP as a
percentage of the total surface area of the slides in the
infarcted region (fig 2). The IgM/complement/CRP positive
surface area in patients with PMN phase infarcts or PMN
phase reinfarcts was significantly greater than that of
patients with early phase infarcts (p = 0.001) or early phase
reinfarcts (p , 0.02). Moreover, this IgM/complement/CRP
positive area tended to be greater in PMN phase reinfarcts
than in PMN phase infarcts (p = 0.54 for IgM, p = 0.58 for
complement; p = 0.70 for CRP). To analyse the correlation
between deposits of IgM, CRP, and complement, we designed
scatter plots in which the IgM/complement/CRP positive
surface area of each patient was plotted, irrespective of
infarct phase. This analysis revealed a linear relation between
the sizes of the IgM and complement deposits (fig 3A;
R = 0.999; p = 0.000), those of IgM and CRP (fig 3B;
R = 0.994; p = 0.000), and those of complement and CRP
(fig 3C; R = 0.996; p = 0.000).
90
70
80
60
40
50
30
20
–10
0
p < 0.02p < 0.001
PMN
phase
Reinfarction
Pe
rc
en
ta
ge
 o
f t
he
 a
re
a 
of
 p
os
iti
vi
ty
 o
f
Ig
M
/C
RP
/c
om
pl
em
en
t o
f t
he
 in
fa
rc
te
d 
zo
ne
N =
10
IgM
Complement
CRP
777
Early
phase
555
Chronic
phase
555
PMN
phase
111111
Early
phase
272727
Control
111
Figure 2 Extent of IgM, complement, and C reactive protein (CRP)
deposition in the infarcted myocardium. Box plot presentation of the
percentage of IgM (grey bars), complement (white bars), and CRP
(shaded bars) positive myocardium. For each patient, the percentage of
positive surface area for the particular antibody in relation to the total
area of the examined tissue was calculated. The error bars represent
minimum and maximum values, whereas the boxes represent the lower
and upper quartiles. The black lines within the boxes represent the
medians (N, the number of patients examined). PMN,
polymorphonuclear leucocyte.
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Figure 3 Scatter plots of the extent of IgM/complement/C reactive
protein (CRP) positive areas in individual patients. Scatter plots in which
the extent of deposition (expressed as per cent of surface) of IgM,
complement, and CRP for each patient are plotted against each other.
(A) IgM versus complement; (B) IgM versus CRP; (C) CRP versus
complement. For each plot, the corresponding correlation coefficient (R)
and the two tailed significance (p value) are given.
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Staining intensity of IgM versus CRP
Because both IgM and CRP can activate complement, we
attempted to assess the contribution of either adaptor
molecule in complement activation by comparing the relative
intensities of staining (fig 4). For this, only PMN phase
infarcts and PMN reinfarcts were analysed because only
these had IgM and CRP deposits. The staining intensity of
IgM and CRP clearly varied between different patients (not
shown). In the 11 examined patients with PMN phase
infarcts, four patients had almost identical IgM and CRP
staining intensity (IgM = CRP). In another four patients,
IgM staining was less intense than that of CRP (IgM , CRP),
whereas in three patients IgM staining was more intense
than that of CRP (IgM . CRP). In three of the seven
examined patients with PMN phase reinfarctions, IgM and
CRP staining intensities were comparable, in one IgM
staining was less intense than that of CRP, and in three
patients IgM stained more intensely than CRP.
DISCUSSION
The observation that complement is locally activated by
infarcted myocardium goes back over 30 years.16 Since then,
it has become apparent that the complement system is an
important mediator of I/R injury in the heart during AMI,
and also in other organs. Studies on the molecular mechan-
isms of I/R induced activation of complement may offer new
clues for treatment. Recent evidence shows that CRP is a
complement activator in human myocardial infarcts.11 Here,
we also provide evidence for the involvement of IgM in this
activation. IgM is a known activator of complement,17–21 and
appeared to be deposited in the infarcted human myocar-
dium. In contrast to Schafer et al,22 who found only weak and
irregular staining of IgM in the infarcted human myocar-
dium, we found complete colocalisation of IgM with
activated C3d and C5b–9, indicative of membrane attack
complex formation. Irrelevant antibody controls indicated
the specificity of the staining for IgM, and IgG staining
yielded negative results. To our knowledge, this is the first
study showing the involvement of IgM in ischaemic injury in
humans.
The deposition of IgM showed a remarkable colocalisation
with that of complement and CRP, strongly suggesting that
the deposited IgM had bound to the same ligands in the
ischaemic heart as CRP. It appears that these ligands are only
exposed during the PMN phase of (re)infarction, because
deposition of CRP and IgM was rarely seen during the other
phases. Currently, we can only speculate about the nature of
these ligands. However, microscopic evaluation revealed that
the plasma membrane of the ischaemic cardiomyocytes in
particular harboured the ligands for IgM and CRP, because
these proteins bound to the plasma membrane of cardio-
myocytes in the infarcted zone. In an earlier study, we
showed that apolipoprotein H, which binds to phosphatidyl-
serine in flip flopped membranes, colocalises with CRP in
ischaemic myocardium.23 Loss of plasma membrane integrity
is a feature of jeopardised cells,24 so that structures exposed in
the flip flopped membrane of jeopardised cardiomyocytes
might serve as ligands for CRP and IgM. Phosphorylcholine is
a good candidate for such a structure because CRP is known
to bind to phosphatidylcholine and particularly to lyso-
phosphatidylcholine via this chemical group.4 6 25 Indeed, a
considerable amount of lyso-phospholipid is generated in the
infarcted myocardium.26 In addition, we have recently
revealed that type II secretory phospholipase A2 (PLA2),
which generates lyso-phospholipids, enhances the binding of
CRP to the plasma membrane of ischaemically challenged rat
cardiomyoblasts.27 Furthermore, we have found that secre-
tory PLA2 colocalises in the infarcted human myocardium
with complement and CRP,28 and therefore also with IgM. A
similar specificity (preferential binding to lyso-phosphatidyl-
choline) has recently be described for anti-phosphorylcholine
IgM.29 This IgM failed to recognise phosphatidyl lipids but did
bind to lyso-phosphatidylcholine on murine apoptotic T cells,
and this binding was dependent on calcium independent
PLA2 activity.
29 It was also revealed that increased IgM
binding to the apoptotic cells was accompanied by comple-
ment activation.29 In addition to lyso-phospholipids, oxidised
phospholipids in membranes may also expose phosphor-
ylcholine in a way that allows the binding of IgM and
CRP,30 31 and increased amounts of oxygen radicals are
known to be generated in myocardial ischaemia.32 Its
supposed specificity for phosphorylcholine is consistent with
the idea that this IgM is natural IgM. Taken together, a
mechanism emerges in which increased production of oxygen
radicals together with enhanced PLA2 activity generates
binding sites in the membrane of cardiomyocytes in the
ischaemic myocardium, which promotes the binding of both
natural IgM and CRP, and which ultimately leads to
activation of complement and subsequent irreversible injury
to the tissue.
We found differences in the staining intensity of CRP and
IgM between patients, suggesting that IgM and CRP
recognise and even compete for the same epitopes on the
membranes of ischaemic cardiomyocytes. Serum levels of
natural IgM vary between people.33 In addition, there are
variations in the magnitude of the CRP response among
patients suffering from AMI.10 Unfortunately, we did not
have the opportunity to analyse the blood samples of the
patients included in our study. Hence, the relation between
circulating IgM and CRP values and the relative contribution
of either protein to complement activation in the ischaemic
myocardium remains to be established in further studies.
Autoimmune diseases such as systemic lupus erythemato-
sus, rheumatoid arthritis, and mixed connective tissue
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Figure 4 Intensity of IgM versus C reactive protein (CRP) deposition in
infarcted areas of the heart. Patients were divided into one of three
groups according to staining intensity: IgM staining intensity comparable
to that of CRP (IgM = CRP, shaded bars), IgM staining less intense than
that of CRP (IgM , CRP, white bars), and IgM staining more intense
than that of CRP (IgM . CRP, grey bars). The numbers of patients in
each group are given within the bars. PMN, polymorphonuclear
leucocyte.
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disease are accompanied by raised concentrations of IgM in
the circulation,34 35 and an increased risk for cardiovascular
events.36 37 In particular, increased concentrations of IgM
autoantibodies against cardiolipin are thought to be the link
between cardiovascular events and IgM in these diseases,
particularly because patients with ischaemic heart disease
may also have raised concentrations of these antibodies.38 39
Our findings could mean that in patients with autoimmune
diseases, during AMI, higher IgM serum values result in
greater IgM deposition in the ischaemic myocardium, thereby
contributing to more extensive injury and a higher mortality.
We included only one patient with autoimmune disease
(scleroderma) in our study. Although this patient did have
very intense staining for IgM in the infarcted myocardium,
the causal link between increased concentrations of anti-
phospholipid IgM autoantibodies and cardiovascular events
in autoimmune disorders needs to be studied further.
Several studies have shown surprising similarities between
CRP and IgM in cardiovascular disease. CRP has been shown
to localise in ischaemic myocardium and to enhance I/R
injury in the heart in a complement dependent manner.9 10 As
we have shown here, IgM also localises in ischaemic
myocardium, and in mouse models enhances I/R injury.12 13
CRP and IgM both enhance foam cell formation by
interacting with lipoprotein particles.40 41 Furthermore, anti-
cardiolipin IgM concentrations constitute a risk factor for
atherosclerotic vascular disease,42 similar to CRP.
The role of natural IgM in vascular disease is not clear,43
and might be considered as two sides of a coin: on the one
hand natural IgM antibodies against oxidised LDL protect
against atherosclerosis, as was found in mice,30 rabbits44 and
in humans,45 supporting the recent view that the induction of
a humoral immune response to oxidised neoepitopes may be
beneficial.46 On the other hand, our results suggest that IgM
antibodies against epitopes in the membranes of ischaemic
cardiomyocytes may enhance cardiac injury during infarction
and constitute an increased risk for cardiovascular disease.
Future studies should reveal the relative contribution of the
effects of IgM on cardiovascular disease in humans.
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